@tourmalinebio.bsky.social
A late-stage clinical biotech developing transformative medicines that establish new standards of care for life-altering inflammatory and immune diseases, including cardiovascular inflammation and thyroid eye disease. $TRML
ICYMI: At #ESCCongress, new TRANQUILITY data showed pacibekitug delivered consistent hs-CRP reductions across subgroups & effects on multiple IL-6-related biomarkers, reinforcing the potential of pacibekitug to address residual inflammatory risk in CVD. https://bit.ly/3HZE1Z1
12.09.2025 16:45 — 👍 0 🔁 0 💬 0 📌 0
Tourmaline Bio Enters into Agreement to be Acquired by Novartis AG Transaction reflects the potential of Tourmaline’s pacibekitug, a long-acting, fully-human, anti-IL-6 monoclonal antibody with best-in-class potential, for the treatment of cardiovascular diseases See our press release at ir.tourmalinebio.com/news for more details
This morning, Tourmaline announced an agreement to be acquired by @novartis.bsky.social. We believe this transaction will accelerate development of pacibekitug, our lead program targeting IL-6, a key driver of inflammation in cardiovascular disease. Read more: bit.ly/45UIbuv #cardiosky #biosky
09.09.2025 11:04 — 👍 1 🔁 0 💬 0 📌 0
New TRANQUILITY data at #ESCCongress 2025 show pacibekitug reduces hs-CRP across subgroups and lowers biomarkers like Lp(a), fibrinogen, and serum amyloid A, reinforcing pacibekitug’s consistent impact on IL-6-related biomarkers.
View poster: https://bit.ly/3HZE1Z1
We’re heading to #ESCCongress 2025 to share additional data from our ongoing Phase 2 TRANQUILITY trial. Learn more about our approach to tackling residual inflammatory risk in cardiovascular disease: https://bit.ly/3HWWtBs #cardiosky
More than 35 million people globally live with abdominal aortic #aneurysm (AAA). Yet there are no FDA-approved medicines to slow or stop its progression. The current treatment paradigm does not address the underlying biology of the disease.
Learn more: bit.ly/4m2Bc8h #Cardiosky #biosky
A new paper in Circulation: Genomic and Precision Medicine explores IL-6 signaling as a case study in drug development informed by human genetics, offering a roadmap for advancing precision therapies in ASCVD. #Cardiosky #biosky
Read more: bit.ly/3J3oXd7
Today, we announced our financial results for the second quarter of 2025 and recent business highlights. See our progress and preview what’s to come in the second half of 2025: bit.ly/45fsVrL
13.08.2025 11:16 — 👍 0 🔁 0 💬 0 📌 0
AAA isn’t just a structural issue; it’s an inflammatory disease. Research shows chronic #inflammation drives damage to the aortic wall, contributing to #aneurysm growth and rupture.
Targeting inflammation could offer a new way forward. Learn more: bit.ly/4m2Bc8h #biosky
We’re proud to feature Famina Hemani, PharmD, as this quarter’s Employee Spotlight. As VP, Head of Pharmacovigilance, she brings deep expertise and a patient-first commitment to our team, ensuring safety remains central as we work to advance meaningful therapies.
28.07.2025 14:34 — 👍 0 🔁 0 💬 0 📌 0
Often called a “ticking time bomb,” abdominal aortic #aneurysm (AAA) is a silent but serious threat. If undetected, an AAA can grow unnoticed until it ruptures- a frequently fatal event.
Despite this, treatment options remain limited. Learn more: bit.ly/3TXwnRr #Cardiosky #biosky
Tourmaline CEO, Sandeep Kulkarni and CFO, Ryan Robinson participated in Leerink Partners’ I&I and Metabolism Forum to discuss IL-6’s role in disease progression and the need for continued innovation in immune and inflammatory diseases.
Learn more: bit.ly/4eHaYWe #biosky
The Tourmaline Bio team at the NASDAQ belling ringing for becoming a publicly-listed biotech company.
👋Join us on the journey.
We’re a clinical-stage biotech exploring IL-6 biology to treat immune & inflammatory diseases, including atherosclerotic cardiovascular disease (ASCVD), thyroid eye disease (TED), & abdominal aortic aneurysm (AAA). $TRML
Meet Tourmaline Bio:
#Cardiosky #EndoSky #Ophthosky
